Clinical Features and Contemporary Management of Patients with Low and Preserved Ejection Fraction Heart Failure: Baseline Characteristics of Patients in the Candesartan in Heart failure—Assessment of Reduction in Mortality and Morbidity (CHARM) Programme

The CHARM Programme provides the largest and most detailed comparison to date of patients low- and preserved-LVEF CHF. It also describes the causes of ACE-inhibitor intolerance in a large cohort of patients and the other treatment which these patients receive.